Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 1
1984 1
1985 1
1986 1
1987 1
1989 2
1990 3
1991 1
1992 2
1993 3
1994 2
1995 3
1996 4
1997 1
1998 1
1999 5
2000 6
2001 7
2002 5
2003 7
2004 11
2005 4
2006 9
2007 10
2008 8
2009 8
2010 8
2011 14
2012 11
2013 18
2014 19
2015 26
2016 12
2017 14
2018 14
2019 7
2020 10
2021 17
2022 17
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group. Mercuri E, et al. N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504. N Engl J Med. 2018. PMID: 29443664 Free article. Clinical Trial.
RESULTS: In the prespecified interim analysis, there was a least-squares mean increase from baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points) and a least-squares mean decrease in the control group (by -1.9 points), with a significant between-group di …
RESULTS: In the prespecified interim analysis, there was a least-squares mean increase from baseline to month 15 in the HFMSE score in the n …
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Parker C, et al. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. N Engl J Med. 2013. PMID: 23863050 Free article. Clinical Trial.
RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The update …
RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival …
A global metagenomic map of urban microbiomes and antimicrobial resistance.
Danko D, Bezdan D, Afshin EE, Ahsanuddin S, Bhattacharya C, Butler DJ, Chng KR, Donnellan D, Hecht J, Jackson K, Kuchin K, Karasikov M, Lyons A, Mak L, Meleshko D, Mustafa H, Mutai B, Neches RY, Ng A, Nikolayeva O, Nikolayeva T, Png E, Ryon KA, Sanchez JL, Shaaban H, Sierra MA, Thomas D, Young B, Abudayyeh OO, Alicea J, Bhattacharyya M, Blekhman R, Castro-Nallar E, Cañas AM, Chatziefthimiou AD, Crawford RW, De Filippis F, Deng Y, Desnues C, Dias-Neto E, Dybwad M, Elhaik E, Ercolini D, Frolova A, Gankin D, Gootenberg JS, Graf AB, Green DC, Hajirasouliha I, Hastings JJA, Hernandez M, Iraola G, Jang S, Kahles A, Kelly FJ, Knights K, Kyrpides NC, Łabaj PP, Lee PKH, Leung MHY, Ljungdahl PO, Mason-Buck G, McGrath K, Meydan C, Mongodin EF, Moraes MO, Nagarajan N, Nieto-Caballero M, Noushmehr H, Oliveira M, Ossowski S, Osuolale OO, Özcan O, Paez-Espino D, Rascovan N, Richard H, Rätsch G, Schriml LM, Semmler T, Sezerman OU, Shi L, Shi T, Siam R, Song LH, Suzuki H, Court DS, Tighe SW, Tong X, Udekwu KI, Ugalde JA, Valentine B, Vassilev DI, Vayndorf EM, Velavan TP, Wu J, Zambrano MM, Zhu J, Zhu S, Mason CE; International MetaSUB Consortium. Danko D, et al. Cell. 2021 Jun 24;184(13):3376-3393.e17. doi: 10.1016/j.cell.2021.05.002. Epub 2021 May 26. Cell. 2021. PMID: 34043940 Free PMC article.
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Maturi RK, et al. JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029. JAMA. 2023. PMID: 36749332 Free PMC article.
RESULTS: Among participants (mean age 56 years; 42.4% female; 5% Asian, 15% Black, 32% Hispanic, 45% White), the 4-year cumulative probability of developing PDR or CI-DME with vision loss was 33.9% with aflibercept vs 56.9% with sham (adjusted hazard ratio, 0.40 [97.5% CI, 0.28 t …
RESULTS: Among participants (mean age 56 years; 42.4% female; 5% Asian, 15% Black, 32% Hispanic, 45% White), the 4-year cumulative probabili …
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS; CHAMPION Trial Study Group. Abraham WT, et al. Lancet. 2011 Feb 19;377(9766):658-66. doi: 10.1016/S0140-6736(11)60101-3. Lancet. 2011. PMID: 21315441 Clinical Trial.
FINDINGS: In 6 months, 83 heart-failure-related hospitalisations were reported in the treatment group (n=270) compared with 120 in the control group (n=280; rate 0.31 vs 0.44, hazard ratio [HR] 0.70, 95% CI 0.60-0.84, p<0.0001). During the entire follow-up (mean 15 mont …
FINDINGS: In 6 months, 83 heart-failure-related hospitalisations were reported in the treatment group (n=270) compared with 120 in the contr …
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana K, Frame FM, Bermudez A, Jose Garcia Marques F, McClurg UL, Wilson L, Thomas H, Buskin A, Hepburn A, Duxfield A, Bastian K, Pye H, Arredondo HM, Hysenaj G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Heer R, Maitland NJ, Whitaker H, Pitteri S, Troyer DA, Wang N, Elliott DJ, Drake RR, Munkley J. Scott E, et al. J Pathol. 2023 Sep;261(1):71-84. doi: 10.1002/path.6152. Epub 2023 Aug 7. J Pathol. 2023. PMID: 37550801 Free article.
Furthermore, we find alpha2,6 sialylated N-glycans expressed by prostate cancer cells can be targeted using the sialyltransferase inhibitor P-3F(AX) -Neu5Ac. Our study identifies an important role for ST6GAL1 and alpha2,6 sialylated N-glycans in prostate cancer progression …
Furthermore, we find alpha2,6 sialylated N-glycans expressed by prostate cancer cells can be targeted using the sialyltransferase inhibitor …
Grazing and ecosystem service delivery in global drylands.
Maestre FT, Le Bagousse-Pinguet Y, Delgado-Baquerizo M, Eldridge DJ, Saiz H, Berdugo M, Gozalo B, Ochoa V, Guirado E, García-Gómez M, Valencia E, Gaitán JJ, Asensio S, Mendoza BJ, Plaza C, Díaz-Martínez P, Rey A, Hu HW, He JZ, Wang JT, Lehmann A, Rillig MC, Cesarz S, Eisenhauer N, Martínez-Valderrama J, Moreno-Jiménez E, Sala O, Abedi M, Ahmadian N, Alados CL, Aramayo V, Amghar F, Arredondo T, Ahumada RJ, Bahalkeh K, Ben Salem F, Blaum N, Boldgiv B, Bowker MA, Bran D, Bu C, Canessa R, Castillo-Monroy AP, Castro H, Castro I, Castro-Quezada P, Chibani R, Conceição AA, Currier CM, Darrouzet-Nardi A, Deák B, Donoso DA, Dougill AJ, Durán J, Erdenetsetseg B, Espinosa CI, Fajardo A, Farzam M, Ferrante D, Frank ASK, Fraser LH, Gherardi LA, Greenville AC, Guerra CA, Gusmán-Montalvan E, Hernández-Hernández RM, Hölzel N, Huber-Sannwald E, Hughes FM, Jadán-Maza O, Jeltsch F, Jentsch A, Kaseke KF, Köbel M, Koopman JE, Leder CV, Linstädter A, le Roux PC, Li X, Liancourt P, Liu J, Louw MA, Maggs-Kölling G, Makhalanyane TP, Issa OM, Manzaneda AJ, Marais E, Mora JP, Moreno G, Munson SM, Nunes A, Oliva G, Oñatibia GR, Peter G, Pivari MOD, Pueyo Y, Quiroga RE, Rahmanian S, Reed SC, Rey PJ, Richard B… See abstract for full author list ➔ Maestre FT, et al. Science. 2022 Nov 25;378(6622):915-920. doi: 10.1126/science.abq4062. Epub 2022 Nov 24. Science. 2022. PMID: 36423285
Serum Proteomic Analysis of Peripartum Cardiomyopathy Reveals Distinctive Dysregulation of Inflammatory and Cholesterol Metabolism Pathways.
Lovell JP, Bermea K, Yu J, Rousseau S, Cohen CD, Bhalodia A, Zita MD, Head RD, Blumenthal RS, Alharethi R, Damp J, Boehmer J, Alexis J, McNamara DM, Sharma G, Adamo L; IPAC; IMAC2 Investigators. Lovell JP, et al. JACC Heart Fail. 2023 Sep;11(9):1231-1242. doi: 10.1016/j.jchf.2023.05.031. Epub 2023 Aug 2. JACC Heart Fail. 2023. PMID: 37542511
RESULTS: Principal component analysis revealed unique clustering of each patient group (P for difference <0.001). Biological pathway analyses of differentially measured proteins in PPCM relative to NPCM, before and after normalization to pertinent healthy controls, high …
RESULTS: Principal component analysis revealed unique clustering of each patient group (P for difference <0.001). Biological pathw …
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.
Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, Nikiphorou E, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Jagtap K, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Chen YM, Makol A, Agarwal V, Patel A, Pauling JD, Wincup C, Barman B, Tehozol EAZ, Serrano JR, La Torre IG, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Hoff LS, Kibbi LE, Halabi H, Vaidya B, Shaharir SS, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA; COVAD study group; Chinoy H, Agarwal V, Aggarwal R, Gupta L. Doskaliuk B, et al. Rheumatol Int. 2023 Sep;43(9):1651-1664. doi: 10.1007/s00296-023-05345-y. Epub 2023 Jun 23. Rheumatol Int. 2023. PMID: 37351634 Free PMC article.

Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZenec

…
Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0 …
Obesity control in Latin American and U.S. Latinos: a systematic review.
Holub CK, Elder JP, Arredondo EM, Barquera S, Eisenberg CM, Sánchez Romero LM, Rivera J, Lobelo F, Simoes EJ. Holub CK, et al. Am J Prev Med. 2013 May;44(5):529-37. doi: 10.1016/j.amepre.2013.01.023. Am J Prev Med. 2013. PMID: 23597819 Free PMC article. Review.
CONTEXT: Latinos are the largest and fastest-growing ethnically diverse group in the U.S.; they are also the most overweight. Mexico is now second to the U.S. in experiencing the worst epidemic of obesity in the world. ...Results can help guide comprehensive evidenc …
CONTEXT: Latinos are the largest and fastest-growing ethnically diverse group in the U.S.; they are also the most overweight. Mexico …
285 results